Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. COR
COR logo

COR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
266.380
Open
254.100
VWAP
260.49
Vol
2.68M
Mkt Cap
50.80B
Low
254.000
Amount
697.82M
EV/EBITDA(TTM)
11.41
Total Shares
194.56M
EV
61.19B
EV/OCF(TTM)
26.88
P/S(TTM)
0.15
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
Show More

Events Timeline

(ET)
2026-05-06
12:00:00
U.S. and Iran Near Agreement, Markets Broadly Higher
select
2026-05-06
06:40:00
FY26 Revenue Growth Outlook Adjusted to 4%-6%
select
2026-05-06
06:40:00
Cencora Reports Q2 Revenue of $78.4B
select

News

NASDAQ.COM
4.5
05-06NASDAQ.COM
US Stocks Surge as Tech Stocks Lead Gains
  • Tech Stocks Rally: The Nasdaq 100 surged 2.08% to reach an all-time high on Wednesday, driven by stellar earnings from chipmakers and AI infrastructure firms, particularly Advanced Micro Devices, which rose over 17% as it raised its full-year sales forecast, reflecting strong investor optimism about ongoing AI investments.
  • Crude Oil Plunge: WTI crude oil prices fell more than 7% to a two-week low as market expectations for a US-Iran peace agreement increased, easing inflation fears and contributing to stock market gains, with the 10-year Treasury yield dropping to a one-week low of 4.33%.
  • Employment Data Impact: The April ADP employment report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, believing it will help maintain a low interest rate environment.
  • International Market Surge: Overseas stock markets closed sharply higher, with the Euro Stoxx 50 rising 2.68% and China's Shanghai Composite gaining 1.17%, indicating a positive global market response to the US economic recovery, further boosting investor confidence.
seekingalpha
9.5
05-06seekingalpha
Cencora Reports Q2 2026 Earnings Highlights
  • Revenue Growth and Adjusted EPS: Cencora reported an adjusted EPS of $4.75 for Q2, reflecting a 7.5% growth, indicating solid operating income growth in both U.S. and International Healthcare Solutions segments, showcasing the company's robust market performance.
  • Full-Year Guidance Raised: Management raised the full-year EPS guidance to a range of $17.65 to $17.90, demonstrating confidence in future profitability, despite lowering revenue growth expectations from 7%-9% to 4%-6%, primarily due to faster brand conversion rates.
  • Cash Flow and Shareholder Returns: Cencora ended March with $2.2 billion in cash and plans to repurchase $1 billion worth of shares by year-end, a move aimed at enhancing shareholder returns and optimizing capital structure.
  • Market Challenges and Strategic Responses: Despite challenges from manufacturer price reductions and customer concentration changes, management remains confident in maintaining operating income growth and emphasizes addressing market dynamics through digital transformation and portfolio optimization.
CNBC
2.0
05-06CNBC
Significant Stock Price Movements for Multiple Companies
  • Arm Holdings Surge: Ahead of its earnings report, Arm Holdings saw a nearly 13% jump on Nasdaq, with UBS analyst raising its 12-month price target from $175 to $245, indicating strong market optimism for its growth potential.
  • Healthpeak Properties Strong Performance: The healthcare REIT soared 18% after first-quarter funds from operations and revenue exceeded Wall Street expectations, raising its second-quarter FFO guidance to $1.71 to $1.75, reflecting robust business momentum.
  • CDW Stock Decline: CDW shares dropped 19% after reporting disappointing operating income in Q1, with adjusted EPS of $2.28 matching consensus, yet the company reaffirmed its 2026 outlook, raising concerns about future performance.
  • Aurora Innovation Partnership: Aurora Innovation's stock rose 9% following a deal to provide driverless technology to Berkshire Hathaway's McLane, which is expected to enhance its competitive edge in the long-haul trucking market.
NASDAQ.COM
4.5
05-06NASDAQ.COM
US Stocks Surge to New Highs Led by Tech Earnings
  • Tech Stock Rally: The Nasdaq 100 index surged over 1.44% to reach an all-time high, driven by strong earnings from chipmakers and AI infrastructure stocks, reflecting market optimism about sustained investment growth in artificial intelligence.
  • Crude Oil Plunge: WTI crude oil prices fell more than 6% to a two-week low as the US nears a peace agreement with Iran, which is expected to lift restrictions on the Strait of Hormuz, thereby reducing energy costs and enhancing profitability prospects for airlines and cruise lines.
  • Employment Data Impact: The April ADP employment change report indicated that US companies added 109,000 jobs, below the expected 120,000, yet the market remains optimistic about the Fed's monetary policy, suggesting a lower likelihood of interest rate hikes.
  • Earnings Optimism: So far, 84% of the 375 S&P 500 companies that reported earnings have exceeded expectations, with Q1 earnings projected to rise 12% year-over-year, indicating strong corporate profitability that further supports the stock market's upward trend.
seekingalpha
9.5
05-06seekingalpha
Cencora Misses Q2 Forecasts, Lowers Growth Outlook
  • Performance Decline: Cencora (COR) reported $78.4 billion in revenue for Q2 and adjusted EPS of $4.75, achieving approximately 4% and 8% year-over-year growth, respectively, but fell short of Wall Street forecasts, resulting in a 52-week low for its shares.
  • Buyback Announcement: The company plans to repurchase $1 billion worth of stock by the end of 2026 and has raised its adjusted EPS outlook to $17.65-$17.90, indicating confidence in future profitability despite current challenges.
  • Growth Outlook Downgrade: While the adjusted EPS forecast has improved, Cencora has lowered its full-year revenue growth outlook from 7%-9% to 4%-6%, reflecting the challenges in the market environment.
  • Industry Impact: Cencora's disappointing results have negatively affected the stock prices of peers, including McKesson (MCK) and Cardinal Health (CAH), highlighting the widespread pressures facing the healthcare distribution sector.
seekingalpha
8.0
05-06seekingalpha
Cencora Declares $0.60 Quarterly Dividend, Consistent with Previous Payouts
  • Dividend Declaration: Cencora has declared a quarterly dividend of $0.60 per share, consistent with previous payouts, indicating the company's stable cash flow and profitability, which enhances investor confidence.
  • Dividend Yield: The forward yield of 0.94% reflects the company's attractiveness in the current market environment, potentially drawing in more investors seeking stable income.
  • Payment Schedule: The dividend will be payable on June 1, with a record date of May 15 and an ex-dividend date also on May 15, providing shareholders with a clear timeline that aids in financial planning.
  • Future Outlook: Cencora is also set to acquire EyeSouth Partners' retina business for $1.1 billion, a move that not only expands its market share but may also enhance overall profitability through business integration.
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
Wall Street analysts forecast COR stock price to rise
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
400.00
Averages
415.38
High
440.00
Current: 0.000
sliders
Low
400.00
Averages
415.38
High
440.00
Morgan Stanley
NULL -> Overweight
downgrade
$400 -> $342
AI Analysis
2026-05-08
New
Reason
Morgan Stanley
Price Target
$400 -> $342
AI Analysis
2026-05-08
New
downgrade
NULL -> Overweight
Reason
Morgan Stanley lowered the firm's price target on Cencora to $342 from $400 and keeps an Overweight rating on the shares.
Baird
Baird
Outperform
to
Outperform
downgrade
$420 -> $339
2026-05-07
New
Reason
Baird
Baird
Price Target
$420 -> $339
2026-05-07
New
downgrade
Outperform
to
Outperform
Reason
Baird lowered the firm's price target on Cencora to $339 from $420 and keeps an Outperform rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for COR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Cencora Inc (COR.N) is 17.33, compared to its 5-year average forward P/E of 15.06. For a more detailed relative valuation and DCF analysis to assess Cencora Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
15.06
Current PE
17.33
Overvalued PE
17.53
Undervalued PE
12.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.33
Current EV/EBITDA
8.66
Overvalued EV/EBITDA
13.65
Undervalued EV/EBITDA
9.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.14
Current PS
0.14
Overvalued PS
0.17
Undervalued PS
0.12

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top stocks in health sector
Intellectia · 38 candidates
Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
866.87B
ABBV logo
ABBV
AbbVie Inc
364.65B
AZN logo
AZN
AstraZeneca PLC
293.00B
MRK logo
MRK
Merck & Co Inc
282.35B
UNH logo
UNH
UnitedHealth Group Inc
254.55B
AMGN logo
AMGN
Amgen Inc
188.63B
run based on daily
Intellectia · 80 candidates
Ticker
Name
Market Cap$
top bottom
SPOT logo
SPOT
Spotify Technology SA
103.40B
COR logo
COR
Cencora Inc
68.24B
AFL logo
AFL
Aflac Inc
56.90B
MSCI logo
MSCI
MSCI Inc
44.25B
ONC logo
ONC
BeOne Medicines AG
40.49B
ED logo
ED
Consolidated Edison Inc
37.48B

Whales Holding COR

D
Dakota Wealth, LLC
Holding
COR
+18.72%
3M Return
G
Graham Capital Management, L.P.
Holding
COR
+17.11%
3M Return
C
Cornerstone Investment Partners, LLC
Holding
COR
+11.63%
3M Return
M
Moran Wealth Management, LLC
Holding
COR
+9.97%
3M Return
S
Staley Capital Advisers, Inc.
Holding
COR
+9.77%
3M Return
D
Diversified Trust Company, Inc.
Holding
COR
+9.51%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cencora Inc (COR) stock price today?

The current price of COR is 261.08 USD — it has increased 2.12

What is Cencora Inc (COR)'s business?

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

What is the price predicton of COR Stock?

Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is415.38 USD with a low forecast of 400.00 USD and a high forecast of 440.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cencora Inc (COR)'s revenue for the last quarter?

Cencora Inc revenue for the last quarter amounts to 78.36B USD, increased 3.85

What is Cencora Inc (COR)'s earnings per share (EPS) for the last quarter?

Cencora Inc. EPS for the last quarter amounts to 8.40 USD, increased 128.26

How many employees does Cencora Inc (COR). have?

Cencora Inc (COR) has 51000 emplpoyees as of May 10 2026.

What is Cencora Inc (COR) market cap?

Today COR has the market capitalization of 50.80B USD.